Low-Dose IL-2 for Treating Moderate to Severe Alopecia Areata: A 52-Week Multicenter Prospective Placebo-Controlled Study Assessing its Impact on T Regulatory Cell and NK Cell Populations - Université de Reims Champagne-Ardenne Access content directly
Journal Articles Journal of Investigative Dermatology Year : 2021

Low-Dose IL-2 for Treating Moderate to Severe Alopecia Areata: A 52-Week Multicenter Prospective Placebo-Controlled Study Assessing its Impact on T Regulatory Cell and NK Cell Populations

Florence Le Duff
Jean-David Bouaziz
Eric Fontas
Michel Ticchioni
Manuelle Viguier
Hôpital universitaire Robert Debré [Reims]
Immuno-Régulation dans les Maladies Auto-Immunes Inflammatoires et le Cancer - EA 7509
Olivier Dereure
Pascal Reygagne
Henri Montaudié
Jean-Philippe Lacour
Sandrine Monestier
Marie-Aleth Richard
Thierry Passeron

Domains

Dermatology Immunotherapy

Arnaud Pommier  : Connect in order to contact the contributor

https://hal.univ-reims.fr/hal-03425030

Submitted on : Friday, November 12, 2021-2:57:33 PM

Last modification on : Tuesday, June 25, 2024-4:52:03 PM

Consult the full text

Dates and versions

hal-03425030 , version 1 (12-11-2021)

Identifiers

Cite

Florence Le Duff, Jean-David Bouaziz, Eric Fontas, Michel Ticchioni, Manuelle Viguier, et al.. Low-Dose IL-2 for Treating Moderate to Severe Alopecia Areata: A 52-Week Multicenter Prospective Placebo-Controlled Study Assessing its Impact on T Regulatory Cell and NK Cell Populations. Journal of Investigative Dermatology, 2021, 141 (4), pp.933 - 936.e6. ⟨10.1016/j.jid.2020.08.015⟩. ⟨hal-03425030⟩

Export

BibTeX XML-TEI Dublin Core DC Terms EndNote DataCite

Collections

URCA IRMAIC
13 View
2 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More